[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_102":103},"en-item",{"_9":10,"_10":11},"kind","item",{"_12":13,"_14":15,"_16":17,"_18":19,"_20":21,"_22":23,"_24":25,"_26":27,"_28":29,"_30":31,"_32":31,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":46,"_47":-5,"_48":49,"_50":-5,"_51":-5,"_52":53,"_54":55,"_56":57,"_58":42,"_59":42,"_60":61,"_62":42,"_63":64},"id","njl5e01gwhmi5wymniicm5gu5","revision",2,"title","Caribou Biosciences启动战略选择评估并计划裁员","originalTitle","Caribou Biosciences, Inc. (0001619856) (Filer)","summary","Caribou Biosciences宣布启动战略选择评估，包括终止vispa-cel和CB-011的临床试验及开发，并计划裁员。预计相关费用约1500万至1900万美元，主要集中在2026年第四季度。公司还计划终止合同、解决知识产权许可安排，并寻求设施转租或终止租赁。","reason","Caribou Biosciences宣布启动战略选择评估，并计划终止部分CAR-T细胞疗法项目的开发及裁员，可能影响其业务方向和财务状况。","source",{"_12":93,"_94":95,"_9":96,"_97":42,"_98":99,"_100":101},"links",{"_90":91,"_78":92},"publishedAt","2026-10-06T20:07:10.000Z","discoveredAt","2026-10-07T00:37:37.193Z","timelineAt","category","ai-products","tags",[84,85,86,87,88,89],"stockSymbols",[83],"score",74,"selected",true,"channel","news","story",{"_73":74,"_16":75},"x","readingMode","full","author","language","body",{"_64":77,"_78":-5,"_79":80,"_81":82},"outline",[],"relatedStories",[76],"indexable","markdownAvailable","group",{"_65":66,"_45":67,"_68":69,"_70":71,"_72":71},"hasTranslation","bodyLanguage","zh","factId","f4-zfx_AjG-A",{"_73":74,"_16":75},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","e3a61d6f-1d0d-4711-aaac-2a0bac11e5f6","Caribou Biosciences启动战略评估并裁员",{"_73":74,"_16":75},"

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 2, 2026

CARIBOU BIOSCIENCES, INC.

(Exact name of Registrant as Specified in Its Charter)

\n\n\n\n\n\n\n\n\n\n\n\n\n\n

Delaware

001-40631

45-3728228

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

2929 7th Street, Suite 105

Berkeley, California 94710

(Address of Principal Executive Offices) (Zip Code)

Registrant’s Telephone Number, Including Area Code: (510) 982-6030

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

\n\n\n

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

\n\n\n

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

\n\n\n

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

\n\n\n

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n	\n	\n	\n
Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		CRBU		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.05 Costs Associated with Exit or Disposal Activities.

On October 2, 2026, the Board of Directors (the “Board”) of Caribou Biosciences, Inc. (the “Company”) approved a restructuring of the Company’s operations (the “Restructuring”) as the Company conducts a process to explore strategic alternatives to maximize stockholder value, including the planned discontinuation of clinical trials and further development activities for the Company’s allogeneic CAR-T cell therapy programs, vispacabtagene regedleucel (“vispa-cel”) and CB-011, a substantial reduction of the Company’s workforce, and other cost reduction measures. The reduction in workforce is anticipated to occur in phases with the majority of affected employees expected to depart in the fourth quarter of 2026 with a limited number of employees expected to remain through completion of the Company’s process of exploring strategic alternatives to support transaction execution and business wind-down activities (the “Workforce Reduction”). The Board took these actions in view of the current financing environment for allogeneic CAR-T cell therapies, which has made it increasingly challenging to secure the capital necessary to responsibly advance the Company’s allogeneic CAR-T cell therapy programs.

公司目前预计与重组相关的总费用将达到约1500万美元至1900万美元，其中大部分预计将在2026年第四季度确认。预计的费用主要包括约1000万美元至1100万美元的一次性遣散费、持续的医疗保险覆盖及相关费用，以及约500万美元至800万美元的用于终止ANTLER一期临床试验和CaMMouflage一期临床试验的未来费用。公司还计划终止相关合同，解决各种知识产权许可安排，并寻求将其设施转租或终止设施租赁的方式。公司目前正在进行一项长期随访研究，针对之前接受过任何公司试验性产品候选人的患者。目前，公司无法就其他费用（包括与公司设施租赁、合同终止或资产减值相关的任何费用）的金额或范围做出善意的估计，并将在做出此类估计后的四个工作日内对本当前报告（表格8-K）进行修订。公司预计会发生的费用和支出及其时间安排取决于若干假设，实际结果可能与此有重大差异。由于重组实施过程中或与之相关的事件可能发生，公司还可能产生其他目前未考虑的费用或现金支出。

第5.02项董事或某些高管的离职；董事的选举；某些高管的任命；某些高管的补偿安排。

公司首席财务官Sriram Ryali的雇佣将于公司就战略选择达成具有约束力的最终协议之日终止，此类终止将根据公司与Ryali先生于2025年1月2日签署的《Ryali雇佣协议》（“Ryali雇佣协议”）中规定的“无因解雇”处理。

根据Ryali雇佣协议中的条款和条件，Ryali先生有权获得Ryali雇佣协议中规定的遣散费和福利。上述描述完全参照Ryali雇佣协议，该协议作为公司2024年12月31日止年度的年度报告（表格10-K）的附件10.51已提交。

第7.01项《联邦法规》第FD条披露。

2026年10月6日，公司发布了一则新闻稿，宣布其决定探索战略选择、重组和裁员计划。本当前报告（表格8-K）的附件99.1附有该新闻稿的副本，并已引用至本第7.01项中。

本第7.01项的信息，包括附件99.1，仅供提供之用，不得视为根据1934年《证券交易法》第18条（以下简称“证券交易法”）“提交”的信息，也不得视为受该条款的任何责任约束，也不得视为在任何根据1933年《证券法》（经修订）或证券交易法提交的文件中被引用，除非在该文件中明确通过具体引用方式提及。

第2页

第8.01项其他事件。

2026年10月2日，董事会批准启动一项流程，以评估战略选择以最大化股东价值，包括但不限于与公司及其资产相关的合并、收购、业务合并或其他战略交易，并批准了其两项同种异体CAR-T细胞治疗项目的进一步开发活动的计划终止，这些项目分别为用于治疗复发或难治性（r/r）B细胞非霍奇金淋巴瘤的vispa-celCB-011。董事会成立了交易委员会，以探索、评估并向董事会就战略选择提出建议。Wedbush Securities Inc.已被聘为公司的独家财务顾问，以协助战略评估过程。公司尚未为完成其战略选择审查设定时间表，且除非董事会已批准行动方案、审查过程结束或另行决定披露是适当或必要的，否则公司无意提供进一步更新。公司无法就此次战略评估过程何时或是否会促成任何类型的交易作出任何承诺，且无法保证此类活动会促成任何能提升股东价值的协议或交易。

前瞻性声明

本表格8-K形式的当前报告包含根据1995年私人证券诉讼改革法案定义的前瞻性声明。在某些情况下，可以通过诸如“可能”、“将”、“应该”、“预期”、“计划”、“预期”、“可能”、“打算”、“目标”、“项目”、“考虑”、“相信”、“估计”、“预测”、“潜力”或“继续”等术语，或这些术语的否定形式或其他类似表达来识别前瞻性声明，尽管并非所有前瞻性声明都包含这些词语。这些前瞻性声明包括但不限于有关公司探索最大化股东价值机会的计划、进入与潜在战略交易相关的任何协议或交易的能力，或如果达成，任何此类协议或交易将成功或在有吸引力的条款上；公司关于成本削减的计划，包括人员缩减的时间和成本；以及其估计现金、现金等价物和可流通证券的充足性。管理层认为这些前瞻性声明在作出时是合理的。然而，这些前瞻性声明受到风险和不确定性的约束，实际结果可能与前瞻性声明所表达或暗示的未来结果有重大差异。风险和不确定性包括但不限于与公司决定停止其同种异体CAR-T细胞治疗项目临床试验和进一步开发相关的风险；战略审查过程，包括识别和执行一项或多项最大化股东价值的交易；实施重组和人员缩减；以及与获得、维护或保护其产品候选人的知识产权相关的其他更一般的风险以及管理相关风险；以及管理费用；以及公司向证券交易委员会（“SEC”）提交的文件中不时描述的其他风险因素，包括其截至2025年12月31日的年度报告表格10-K以及后续的SEC文件。鉴于这些前瞻性声明中存在重大不确定性，您不应将前瞻性声明作为对未来事件的预测。除法律要求外，公司不承担因任何原因公开更新任何前瞻性声明的义务。

第9.01项财务报表和附录。

(d) 附录

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n\n	\n
附录编号		描述
\n
99.1		Caribou Biosciences, Inc.于2026年10月6日发布的新闻稿（随附提供）
\n
104		封面页面交互式数据文件（嵌入在内联XBRL文档中）

第3页

签名

根据1934年证券交易法案（经修订）的要求，注册人已 duly 促使本报告由此处 duly 授权的代表签署。

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n\n	\n	\n\n	\n	\n\n	\n
\n		\n		CARIBOU BIOSCIENCES, INC.
\n	\n	\n
日期：2026年10月6日		\n		由：		/s/ Rachel E. Haurwitz
\n		\n		\n		Rachel E. Haurwitz
\n		\n		\n		总裁兼首席执行官

第4页

","original","zhKind","translation","complete",false,"CRBU","公司与财报","行业与主题","政策与监管","观点与解读","其他","宏观与美联储","aihot","/items/njl5e01gwhmi5wymniicm5gu5","https://www.sec.gov/Archives/edgar/data/1619856/000119312526415559/0001193125-26-415559-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1791590400&sig=4febbd6b569486c4","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1791590400&sig=b2d04423d06d263c 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1791590400&sig=6668906c0ecbb2a7 96w","changelogVersion","2026-10-01T08:00"]